Versantis is a clinical-stage company developing transformative orphan drugs that fill the medical gap in the care of liver and pediatric diseases. It has been acquired by GENFIT in 2022.

Products, services, technology

VS-01-ACLF phase 2-stage; FDA orphan-designated in acute-on-chronic liver failure. VS-01-UCD preclinical-stage; FDA orphan-designated in acute pediatric hyperammonemia. VS-02 oral, small molecule for chronic hepatic encephalopathy (HE). TS-01 point-of-care diagnostic device to manage HE at home.

Location
Canton
Facts & figures
  • Type of organization
    Other
  • Year of foundation
    2015
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in